Stem Cell Treatment for a Stroke is an option
What is a Stroke?
A stroke (Cerebrovascular Accident or CVA), is the rapid loss of brain function due to the blood supply to the brain being disturbed. This can be from ischemia from the lack of blood flow or from a blockage known as Thrombosis, an Arterial Embolism, or a Haemorrhage where blood is leaking out or inside the brain.
The affected area of the brain is unable to function correctly and may result in an inability to move especially in one or more limbs on one side of the body. Stroke can also cause an inability to understand speech or speak or see properly.
A stroke is a medical emergency that needs immediate medical attention. Stroke can cause permanent neurological damage and ongoing complications, and death. It is the a leading cause of adult disability in the around the world.
Risk factors for stroke include ederly people, high blood pressure (hypertension), a previous stroke or from a transient ischemic attack (TIA).
Other related risk conditions include diabetes, high cholesterol, cigarette smoking and atrial fibrillation. High blood pressure is the most important modifiable risk factor of stroke.
A silent stroke is a stroke that does not have any outward symptoms, and the patient is typically unaware they have suffered a stroke. A silent stroke still causes damage to the brain, and places the person at risk for both transient ischemic attack and a major stroke occuring in the future.
People who have suffered a major stroke are at risk of having silent strokes as well.
Lancet. 2011 May 14;377(9778):1693-702
Authors: Langhorne P, Bernhardt J, Kwakkel G
Stroke is a common, serious, and disabling global health-care problem, and rehabilitation is a major part of patient care. There is evidence to support rehabilitation in well coordinated multidisciplinary stroke units or through provision of early supported provision of discharge teams. Potentially beneficial treatment options for motor recovery of the arm include constraint-induced movement therapy and robotics.
Promising interventions that could be beneficial to improve aspects of gait include fitness training, high-intensity therapy, and repetitive-task training. Repetitive-task training might also improve transfer functions. Occupational therapy can improve activities of daily living; however, information about the clinical effect of various strategies of cognitive rehabilitation and strategies for aphasia and dysarthria is scarce. Several large trials of rehabilitation practice and of novel therapies (eg, stem-cell therapy, repetitive transcranial magnetic stimulation, virtual reality, robotic therapies, and drug augmentation) are underway to inform future practice.
PMID: 21571152 [PubMed - in process]
Stem Cell Treatment for Stroke NIH Streaming Database:
Neuroprotective and regenerative roles of intranasal Wnt-3a Administration after focal ischemic stroke in mice.
Neuroprotective and regenerative roles of intranasal Wnt-3a Administration after focal ischemic stroke in mice. J Cereb Blood Flow Metab. 2017 Jan 01;:271678X17702669 Authors: Wei ZZ, Zhang JY, Taylor TM, Gu X, Zhao Y, Wei L Abstract Wnt signaling is a conserved pathway involved in expansion of neural progenitors and lineage specification during development. However, the role of Wnt signaling in the post-stroke brain has not been well-elucidated. We hypothesized that Wnt-3a would play an important role for neurogenesis and brain repair. Adult male mice were subjected to a focal ischemic stroke targeting the sensorimotor cortex. Mice that received Wnt-3a (2 µg/kg/day, 1 h after stroke and once a day for the next 2 days, intranasal delivery) had reduced infarct volume compared to stroke controls. Wnt-3a intranasal treatment of seven days upregulated the expression of brain-derived growth factor (BDNF), increased the proliferation and migration of neuroblasts from the subventricular zone (SVZ), resulting in increased numbers of newly formed neurons and endothelial cells in the peri-infarct zone. Both the molecular and cellular effects of Wnt-3a were blocked by the Wnt specific inhibitors XAV-939 or Dkk-1. In functional assays, Wnt-3a treatment enhanced the local cerebral blood flow (LCBF) in the peri-infarct, as well as improved sensorimotor functions in a battery of behavioral tests. Together, our data demonstrates that the Wnt-3a signaling can act as a dual neuroprotective and regenerative factor for the treatment of ischemic stroke. PMID: 28430000 [PubMed - as supplied by publisher]Read more...